Glofitamab Bridging ASCT for Patients With Relapsed or Refractory DLBCL

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	More info	NCT ID
Glofitamab Bridging ASCT for Patients With Relapsed or Refractory DLBCL	B-cell neoplasm, Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, diffuse large B-cell lymphoma, immune system disorder, immunoproliferative disorder, lymphatic system disorder, lymphoma, lymphoproliferative syndrome, neoplasm	Recruiting	Phase 2	2025-07-14		NCT06682130

1 results · Page 1 of 1

Swipe the table sideways for more columns.

Organizations	Linked trials
The First Affiliated Hospital of Soochow University	164

1 results · Page 1 of 1

Swipe the table sideways for more columns.

Research sites	City	Country	Linked trials
The First Affiliated Hospital of Soochow University	Suzhou	China	101

Clinical trials